In this study, the authors administered the cyclooxygenase-2 inhibitor celecoxib concurrent with the cisplatin and irinotecan doublet during the C-CRT course of unresectable locally advanced NSCLC patients. Here, PTGS2 is linked to non-small cell lung carcinoma.